



Recently Presented Data Demonstrate Benefits of CHF Solutions' Aquadex FlexFlow® System in Managing Fluid Overload in Heart Failure Patients from the United Kingdom

September 20, 2018

EDEN PRAIRIE, Minn., Sept. 20, 2018 (GLOBE NEWSWIRE) -- CHF Solutions, Inc. (Nasdaq:CHFS) announced today results from a poster recently presented by a United Kingdom's National Health Service hospital that demonstrated ultrafiltration provides a safe and effective alternative means of fluid removal in diuretic-resistant heart failure patients.

The prospective data, which were presented at the most recent British Cardiovascular Society annual conference, showed greater weight loss over a shorter treatment period with ultrafiltration compared to IV diuretics alone, without impacting renal function. In addition, use of the Aquadex FlexFlow system resulted in improved BNP levels and often enabled fewer hospital days. The independent study collected data from thirteen patients who underwent ultrafiltration between January 2014 and June 2017.

"We believe the results from this poster, continue to provide evidence for the benefit of utilizing the Aquadex FlexFlow system to reduce fluid overload in heart failure patients," said John Erb, chairman and CEO of CHF Solutions. "These data reinforce our belief in these benefits and reinforce our current strategy to grow the Aquadex FlexFlow system worldwide and provide healthcare professionals with an additional therapy option for the treatment of fluid overload."

About CHF Solutions

CHF Solutions, Inc. (Nasdaq:CHFS) is a medical device company focused on commercializing the Aquadex FlexFlow system for Aquapheresis therapy. The Aquadex FlexFlow system is indicated for temporary (up to eight hours) ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy, and extended (longer than 8 hours) ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy and require hospitalization. All treatments must be administered by a healthcare provider, under physician prescription, both of whom having received training in extracorporeal therapies. The company's mission is to predict, measure, and control patient fluid balance through science, collaboration, and innovative medical technology. CHF Solutions is a Delaware corporation headquartered in Minneapolis, Minnesota with wholly owned subsidiaries in Australia and Ireland. The company has been listed on the Nasdaq Capital Market since February 2012.

Forward-Looking Statements

Certain statements in this release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, the statements regarding the benefits from using the Aquadex FlexFlow and our strategy to grow the Aquadex FlexFlow system worldwide and provide healthcare professionals with an additional therapy option for the treatment of fluid overload. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risk associated with our ability to execute on our recently announced strategic realignment, the possibility that we may be unable to raise sufficient funds necessary for our anticipated operations, our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. CHF Solutions does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

CONTACTS:

INVESTORS:

Claudia Napal Drayton
Chief Financial Officer
CHF Solutions, Inc.
952-345-4205
ir@chf-solutions.com

-or-

Bret Shapiro
Managing Partner
CORE IR
516-222-2560
brets@coreir.com
www.coreir.com

MEDIA

Jules Abraham
JQA Partners, Inc.
917-885-7378
jabraham@jqapartners.com



Source: CHF Solutions, Inc.